DEEP RESEARCH · HANMI PHARMACEUTICAL

Hanmi Pharmaceutical Pipeline Analysis: Strategic Focus on Metabolic Disease and Competitive Positioning in the Global Obesity Market

Maturation of the "Korean-style R&D model" — H.O.P. project rewrites the "quality of weight loss" paradigm

Date: 2025-09-07 · Pipeline analysis · Original Naver Blog post

0. Bottom line first

• Strategic inflection: The role of incrementally-improved/combination drugs as the R&D funding source is giving way to the innovative pipeline itself — led by obesity drugs — as the primary driver of enterprise value.
• Differentiation axis: Not a "me-too" play. Targeting both Best-in-Class (HM15275) and First-in-Class (HM17321). The contest is not headline efficacy numbers but the "quality of weight loss" — i.e., muscle preservation.
• Diversification: 15 oncology programs + 5 rare-disease programs (21 orphan-drug designations across the US and Europe) reduce single-area dependence.
• Milestones to watch: HM15275 Phase 2 start and data, HM17321 IND filing and Phase 1 data, and the domestic launch of efpeglenatide in H2 2026.

1. R&D philosophy and strategic focus

1.1. Maturation of the "Korean-style R&D model"

Official fact: Hanmi reinvests cash flow from commercially successful incremental/combination drugs (Amosartan, Rosuzet) into innovative first-in-class drug development. R&D-to-revenue ratio is sustained above 14%.

Interpretation: The model has delivered a solid financial base, and the company has now reached an inflection where the obesity pipeline itself drives valuation — the long-term strategy of decades is bearing fruit.

1.2. Three pillars of innovation

1.3. Key findings

• Lead pipeline: The obesity portfolio, managed since 2023 under the "H.O.P. (Hanmi Obesity Pipeline) project," takes a diversified, multi-asset approach rather than relying on a single drug.
• Competitive stance: HM15275 targets Best-in-Class; HM17321 targets First-in-Class. Both directly attack the clinical limitations of dominant therapies — particularly muscle preservation.
• Growth engines: 15 oncology + 5 rare-disease programs provide long-term optionality.
• Partnerships: Robust global partner network. Recent shift: take key assets through early clinical proof-of-concept in-house before seeking partners — intended to maximize licensing value.

2. H.O.P. project: deep dive into the obesity pipeline

2.1. Strategic challenge — redefining the "quality of weight loss"

The dominant GLP-1 class delivers strong weight loss but has clear limitations:

• Sarcopenia risk: up to 40% of total weight lost can come from muscle
• Common GI side effects (nausea, vomiting, diarrhea)
• "Yo-yo effect" — weight rebound after discontinuation

2.2. Best-in-Class challenger — HM15275 (LA-GLP/GIP/GCG triple agonist)

Official fact: HM15275 is a long-acting triple agonist designed to engage three hormone receptors simultaneously. (Hanmi HM15275 pipeline page)

Interpretation: Target profile = bariatric-surgery-level weight loss (25-30%) or beyond, with minimized muscle loss, plus add-on CVRM (cardio-vascular-renal-metabolic) benefit. Best-in-Class positioning.

Clinical development status:

• Phase 1 (single & multiple ascending dose) in healthy adults and obese patients completed — safety, tolerability, and PK suitable for once-weekly dosing. (BioSpectator: FDA IND clearance)
• 2025 ADA (American Diabetes Association): Top-dose cohort showed ~4.81% mean weight loss vs. placebo after just 4 weeks; one participant lost up to 10.64% by day 43 — comparable to early Phase 2 data from Lilly's retatrutide. (Chosun Biz: 11% weight loss, KorMedi: 4.8% in 4 weeks, BioSpectator)
• Phase 2 IND filed with FDA in July 2025 and Korea's MFDS in August 2025. Long-term Phase 2 with doses including 8 mg+ to start within the year. (Hanmi press: Best-in-Class data, Pharm Edaily)

2.3. First-in-Class innovator — HM17321 (LA-UCN2, CRF2 agonist)

Official fact: HM17321 is a long-acting Urocortin 2 (UCN2) derivative that selectively activates the CRF2 (Corticotropin-Releasing Factor 2) receptor — outside the incretin (GLP-1/GIP) system. It is engineered to selectively reduce adipose tissue while stimulating protein synthesis in muscle to increase muscle mass. (Hanmi HM17321 press, PharmNews: "game changer")

Interpretation: The aim is the world's first therapy to break the link between weight loss and muscle loss, addressing GLP-1's largest weakness. Use cases include monotherapy for sarcopenic obesity or combination with GLP-1 — maximizing fat loss while preserving optimal body composition.

Preclinical evidence and status:

• At Obesity Week, preclinical data in obese animal models showed weight loss comparable to semaglutide (Wegovy) plus a significant increase in lean mass / muscle mass. (ZDNet Korea, Hanmi press release (2024-11-06))
• Not just mass — muscle function recovered to normal levels in functional assessments.
• Currently preclinical. IND submission and Phase 1 initiation planned this year. (Hankyung at JPMHC 2025: GLP-1 combo addresses sarcopenia)

2.4. Market-entry vanguard — efpeglenatide (GLP-1 agonist)

Official fact: A long-acting GLP-1 receptor agonist with a mechanism similar to Wegovy/Ozempic. The aim is speed-to-market rather than novelty, targeting Korea's domestic market first. A large Phase 3 in 420 Korean obese patients is ongoing. Launch target was pulled forward from 2027 to H2 2026. (Hanmi press, Pharm Edaily)

3. The global obesity competitive landscape

3.1. Incumbents — Wegovy and Zepbound

Novo Nordisk Wegovy (semaglutide): A pure GLP-1 receptor agonist. Mimics endogenous GLP-1 — suppresses appetite via the hypothalamus, delays gastric emptying, stimulates insulin secretion. ~15% mean weight loss and meaningful cardiovascular benefit demonstrated. Limitations: GI side effects and muscle loss. (Wegovy - Namu wiki, Hidoc, Chosun Ilbo)

Eli Lilly Zepbound (tirzepatide): The world's first GLP-1/GIP dual receptor agonist. ~20%+ mean weight loss — approaching bariatric-surgery territory and setting a new efficacy bar. Shares Wegovy's GI side-effect and muscle-loss limitations. (Yakup News: Zepbound FDA approval, PharmNews: Zepbound surpasses Wegovy, Chosun Biz: 8kg more than Wegovy)

3.2. Hanmi's strategic differentiation

• HM15275 vs. Zepbound: The key is the addition of GCG. Zepbound (GLP-1/GIP) primarily acts on the "intake" side (satiety); HM15275 simultaneously attacks the "expenditure" side (energy metabolism) via GCG. Scientific rationale for >25% weight loss and improved lipid metabolism.
• HM17321 vs. the entire incretin class: Does not compete on weight loss %. It opens a new category — "metabolic health + functional muscle strength" — and offers a uniquely suitable option for older patients at high sarcopenia risk.
• Efpeglenatide vs. Wegovy/Zepbound (Korea): Competes on "access and value," not clinical superiority — a stable, economical alternative in a market characterized by high prices and intermittent supply shortages.

3.3. Comparison of leading obesity candidates

4. Diversified growth engines — oncology and rare-disease pipelines

4.1. Oncology portfolio — 15 assets, breadth and depth

Hanmi has a sweeping oncology pipeline of 15 individual assets — diverse targets plus expansion into next-gen modality platforms. (Hanmi innovative pipeline, Pipeline snapshot)

4.2. Rare-disease portfolio — high-value niche strategy

Official fact: Across 7 pipeline assets, Hanmi has secured 21 orphan-drug designations (ODD) in the US, Europe, and Korea — the most among Korean pharma. ODD brings 7-year US market exclusivity, tax credits, application-fee waivers, and priority review — strong commercial and regulatory leverage. (News1: 21 ODDs across 7 candidates)

5. Strategic alliances and global partnerships

5.1. The "house of out-licensing" — a hybrid model

Hanmi has built a reputation as Korea's premier out-licensor over many years. (Company history, Pharm Edaily out-licensing deep dive, Daily Pharm: deal-size rankings) The current partnership model is a hybrid: early-stage out-licensing + joint development + regional commercialization deals.

5.2. Key partners

• MSD (Merck): Co-developing the MASH therapy efinopegdutide (GLP-1/GCG).
• Roche / Genentech: Partner for the pan-RAF inhibitor belvarafenib.
• Aptose Biosciences: Development and commercialization of the AML therapy tuspetinib.
• Assertio Holdings: Partner for Rolontis (neutropenia) and Poziotinib (lung cancer).
• GC Biopharma (GC Green Cross): Co-developing the Fabry-disease therapy LA-GLA.
• Beijing Hanmi Pharm: Core R&D hub for innovative-drug development including the bispecific antibody platform Pentambody (BH3120).
• Silanes: Commercialization partner for Mexico and Latin America. (TheBioNews: Silanes tours Paltan plant)
• Samsung Bioepis: Co-promotion of biosimilars (osteoporosis). (Hanmi · Samsung Bioepis agreement)
• Medic Life Sciences: New oncology co-research and other emerging alliances. (Ilyo Weekly)

Interpretation: Notable shift: Hanmi is now advancing key assets like HM15275 and HM17321 through early clinical proof-of-concept in-house before seeking partners. By eliminating early-stage uncertainty and securing a strong data package, it positions itself to negotiate licensing deals from a position of strength — better upfronts, better royalty splits.

6. SWOT and final assessment

6.1. SWOT

6.2. Final assessment

Key milestones to watch:

1. HM15275 Phase 2 initiation and data
2. HM17321 IND filing and Phase 1 data — the validation point for the "game changer" thesis
3. Efpeglenatide domestic launch in H2 2026 — a test of commercial execution

Successful development of the obesity pipeline could be the decisive launchpad for Hanmi to move beyond a Korean leader and become a global innovative-drug company.